Understanding of Prognosis and Estimation of Mortality in Ambulatory Patients With Heart Failure
In this cohort study, discordant optimism regarding life expectancy compared with model estimates was common and associated with mortality that was not due to a lower probability of receiving a heart transplant or VAD. The findings suggest clinicians should objectively evaluate HF risk when considering advanced therapies, rather than relying primarily on patient-reported symptoms.
Authors
- Thomas Cascino (ORCID: https://orcid.org/0000-0003-3779-0790)
- Colleen K. McIlvennan (ORCID: https://orcid.org/0000-0003-2131-9910)
- S. Shore
- Blair Richards (ORCID: https://orcid.org/0009-0009-1440-7040)
- Wayne C. Levy (ORCID: https://orcid.org/0000-0003-1530-2194)
- James Stewart
- Josef Stehlik
- Geoffrey D. Barnes
- Garrick C. Stewart
- Keith D. Aaronson
- Grace Herron
- Neal Jeffries
- Douglas L. Mann
- Wendy C. Taddei-Peters
Institutions
- Brigham and Women's Hospital (US)
- National Institutes of Health (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- University of Utah (US)
- University of Michigan (US)
- National Heart, Lung, and Blood Institute (US)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-03-03
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.0328
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Pfizer
- AstraZeneca
- Sanofi
- University of Washington
- Boston Scientific Corporation
- ZOLL Medical Corporation
- CareDx
- Impulse Dynamics
- National Institutes of Health
- Michigan Institute for Clinical and Health Research
- National Heart, Lung, and Blood Institute
- National Center for Advancing Translational Sciences